Industry Focus

It’s Halloween and we’ve got a special show for you. Motley Fool Contributor Dan Kline joins the show and we break down our biggest fears in the market today, list out the stocks we think are going t…

Biogen's drug pipeline took a massive hit earlier this year when it stopped development of its Alzheimer's disease drug, aducanumab, for a lack of efficacy. Now, Biogen says new data shows it may wor…

Founded by Katrina Lake in 2011, StitchFix has taken the fashion world by storm. By leveraging data science, StitchFix sends customers personalized “fixes” tailored toward their size and style, and t…

Earnings season is in full swing, and in this week’s Industry Focus: Financials, host Jason Moser and Fool.com contributor Matt Frankel, CFP discuss the latest results from PayPal (NASDAQ: PYPL) and …

It's been a tumultuous couple of months since we did our S-1 show on co-working start up The We Company (or WeWork). Fellow IF host Nick Sciple hops on to walk through what has happened over the past…

Tesla shocked the investing world on Wednesday night, reporting a surprise profit and positive free cash flow in its third quarter earnings report. Motley Fool Analysts Jim Mueller and Jim Gillies jo…

2019 has been a banner year for big name IPOs, but several newly minted public companies have flow under-the-radar of most investors.  On this episode of Industry Focus: Healthcare, host Shannon Jone…

On this week’s episode of Industry Focus: Consumer Goods host Jason Moser and Fool.com contributor Asit Sharma take a closer look at Land's End and Herman Miller, two sleeper stocks with some big pot…

Earnings season is now in full swing, and most major U.S. banks have reported. In today’s Industry Focus: Financials, host Jason Moser and Fool.com contributor Matt Frankel, CFP discuss the results f…

We're back with another deep dive on a software company currently undergoing the transition from the license model to SaaS -- Manhattan Associates. We run the company through contributor Brian Ferold…

With the cost of solar energy plummeting and an aging energy grid, solar is poised for rapid growth. As solar grows, so will demand for solar components, like the inverters made by Enphase and Solar …

Pfizer's latest phase 3 trial results put its promising eczema drug on a path to challenge Regeneron and Sanofi's $2 billion-per-year drug, Dupixent. Also, how Regenxbio and Adverum Biotechnologies h…

Chanticleer Holdings, the company that owns a handful of Hooters locations along with other eateries in the burger space is being purchased by Sonnet BioTherapeutics Inc., a company that makes cancer…

More CEOs are leaving their companies in 2019 than ever before. In today’s Industry Focus: Financials, our team breaks down why we’re seeing a record number of CEO departures and whether or not it’s …

Facebook CEO Mark Zuckerberg recently made comments about the company's ability to defend itself from anti-trust proceedings, so we revisit Senator Elizabeth Warren's outline for how and why companie…

With oil and gas production exploding in the U.S., takeaway capacity is running low, leading to oversupply and even flaring of unwanted natural gas that producers can’t get to market. That creates op…

Here's why post-approval setbacks have caused Puma Biotechnology, Clovis Oncology, and Regenxbio shares to tumble, and if any of these stocks are finally worth buying. Stocks: PBYI, CLVS, RGNX

Check …

These days it seems like all the struggling retailers are taking their strongest performing brands and spinning them out from the larger parent companies. J Crew plans to take its Madewell brand publ…

Over the past week, four major brokerages have decided to scrap their trading commissions. In this episode of Industry Focus: Financials, host Jason Moser and Fool.com contributor Matt Frankel, CFP d…

We answer a listener email asking about the ins and outs of the IPO process:

- How IPOs work - Why IPO prices can change - And how a company like WeWork can decide to pull its IPO

Check out more of o…